Savara (SVRA) Interest & Investment Income (2010 - 2026)
Savara (SVRA) posted quarterly Interest & Investment Income of -$247000.0 for Q1 2026, down 60.39% year-over-year from -$623573.8 in Q1 2025, and down 314.78% quarter-over-quarter from $115000.0 in Q4 2025.
Powered by 
Analysis
Savara (SVRA) Interest & Investment Income (2010 - 2026) Analysis & Trends
Savara (SVRA) has reported Interest & Investment Income for 17 consecutive years, with -$247000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest & Investment Income fell 60.39% year-over-year to -$247000.0; the TTM figure through Mar 2026 stood at -$95000.0 (down 167.38% YoY), while the FY2025 annual figure was -$2000.0, down 104.55% from the prior year.
- Interest & Investment Income fell to -$247000.0 in Q1 2026 per SVRA's latest filing, from $115000.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $583000.0 in Q3 2024 and bottomed at -$263000.0 in Q4 2024.
- Historically, Interest & Investment Income has averaged $2000.0 across 5 years, with a median of -$5000.0 in 2023.
- On a YoY basis, Interest & Investment Income climbed as much as 11760.0% in 2024 and fell as far as 1892.86% in 2024.
- Savara's Interest & Investment Income stood at $29000.0 in 2022, then jumped by 768.97% to $252000.0 in 2023, then tumbled by 204.37% to -$263000.0 in 2024, then soared by 143.73% to $115000.0 in 2025, then plunged by 314.78% to -$247000.0 in 2026.
- Business Quant data shows SVRA's Interest & Investment Income at -$247000.0 in Q1 2026, $115000.0 in Q4 2025, and $123000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Savara | 1.36 Bn | 1.36 Bn | - | 829,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 829,000.00 |
| Mar 31, 2026 | 1.06 Mn |
| Dec 31, 2025 | 1.20 Mn |
| Sep 30, 2025 | 548,000.00 |
| Jun 30, 2025 | 921,000.00 |
| Mar 31, 2025 | 1.50 Mn |
| Dec 31, 2024 | 1.91 Mn |
| Sep 30, 2024 | 2.13 Mn |
| Jun 30, 2024 | 1.07 Mn |
| Mar 31, 2024 | 1.35 Mn |
| Dec 31, 2023 | 1.52 Mn |
| Sep 30, 2023 | 1.44 Mn |
| Jun 30, 2023 | -60,000.00 |
| Mar 31, 2023 | 14,000.00 |
| Dec 31, 2022 | 614,000.00 |
| Sep 30, 2022 | 152,000.00 |
| Jun 30, 2022 | 20,000.00 |
| Mar 31, 2022 | -88,000.00 |
| Dec 31, 2021 | -565,000.00 |
| Sep 30, 2021 | -566,000.00 |